Ulysses Pharmacuticalprivate Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 09-12-2024
- Paid Up Capital ₹ 0.63 M
as on 09-12-2024
- Company Age 23 Year, 5 Months
- Last Filing with ROC 31 Mar 2017
- Satisfied Charges ₹ 9.25 M
as on 09-12-2024
- Revenue %
(FY 2017)
- Profit 44.95%
(FY 2017)
- Ebitda 44.58%
(FY 2017)
- Net Worth -6.89%
(FY 2017)
- Total Assets -0.82%
(FY 2017)
About Ulysses Pharmacuticalprivate
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2017. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.63 M.
The company has closed loans amounting to ₹9.25 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Pratim Banerji and Siddhartha Mitra serve as directors at the Company.
- CIN/LLPIN
U24232WB2001PTC093516
- Company No.
093516
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
27 Jul 2001
- Date of AGM
29 Sep 2017
- Date of Balance Sheet
31 Mar 2017
- Listing Status
Unlisted
- ROC Code
Roc Kolkata
Industry
Company Details
- Location
Kolkata, West Bengal, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Ulysses Pharmacuticalprivate?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pratim Banerji  | Managing Director | 27-Jul-2001 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Siddhartha Mitra | Director | 10-Feb-2014 | Current |
Financial Performance of Ulysses Pharmacuticalprivate.
Ulysses Pharmacuticalprivate Ltd, for the financial year ended 2017, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 44.95% increase in profit. The company's net worth dipped by a decrease of 6.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ulysses Pharmacuticalprivate?
In 2017, Ulysses Pharmacuticalprivate had a promoter holding of 35.30% and a public holding of 64.70%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 08 Apr 2003 | ₹9.25 M | Satisfied |
How Many Employees Work at Ulysses Pharmacuticalprivate?
Unlock and access historical data on people associated with Ulysses Pharmacuticalprivate, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ulysses Pharmacuticalprivate, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ulysses Pharmacuticalprivate's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
